A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214 monotherapy, and in combination with bevacizumab or pembrolizumab, in participants with microsatellite instability (MSI) and/or deficient mismatch repair (dMMR) advanced solid tumors. VVD-133214 is an oral drug that acts on a protein called Werner (WRN), which may promote the growth of cancers that are MSI and/or dMMR. By acting on WRN, VVD-133214 may be able to block the growth of these types of cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Dobry ogólny stan zdrowia (ECOG 0-1, czyli możliwość wykonywania codziennych czynności)
- •Zaawansowany nowotwór stały z określonymi zmianami genetycznymi (MSI lub dMMR) potwierdzonymi badaniem
- •Wcześniejsze leczenie standardowe, które nie zadziałało lub pacjent go nie tolerował
- •Możliwość zmierzenia wielkości nowotworu na badaniach
- •Oczekiwana długość życia minimum 12 tygodni
- •Dostęp do zapiętrzenia tkanki nowotworowej (archiwum) lub możliwość pobrania nowej próbki
- •Prawidłowe parametry krwi i funkcja serca i nerek
✗ Disqualifies
- •Niezdolność do połykania tabletek
- •Zaburzenia wchłaniania leków z przewodu pokarmowego
- •Uczulenie na składniki leku lub rzadkie zaburzenia genetyczne (galaktozemią, nietolerancję glukozo-galaktozy, niedobór laktozy)
- •Przerzuty do mózgu, które się rozwijają lub wymagają leczenia lekami uspokajającymi lub sterydami
- •Aktywne lub niekontrolowane infekcje bakteryjne, wirusowe lub grzybiczne
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 23, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (38)
City of Hope Cancer Center
Duarte, United States
City of Hope at Irvine Lennar
Irvine, United States
START Los Angeles
Los Angeles, United States
Emory University School of Medicine
Atlanta, United States
Norton Cancer Institute - MDC
Louisville, United States
University of Michigan
Ann Arbor, United States
START Midwest
Grand Rapids, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, United States
Duke University
Durham, United States
Oklahoma University Health Sciences Center
Oklahoma City, United States
SCRI Oncology Partners
Nashville, United States
MD Anderson Cancer Center
Houston, United States
START San Antonio
San Antonio, United States
START Mountain Region
West Valley City, United States
St Vincents Sydney
Darlinghurst, Australia
Alfred Hospital
Melbourne, Australia
UZ Leuven Gasthuisberg
Leuven, Belgium
BCCA-Vancouver Cancer Centre
Vancouver, Canada
Princess Margaret Cancer Center
Toronto, Canada
Rigshospitalet
København Ø, Denmark
CLCC Leon Berard Lyon
Lyon, France
Gustave Roussy
Villejuif, France
Sarawak Public Hospital
Kuching, Malaysia
Kyungpook National University Chilgok Hospital
Daegu, South Korea
National Cancer Center
Gyeonggi-do, South Korea
Seoul National University Bundang Hospital
Seongnam-si, South Korea
Seoul National University Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Severance Hospital
Seoul, South Korea
Vall d'Hebron Institute of Oncology (VHIO), Barcelona
Barcelona, Spain
Clinica Universidad de Navarra Madrid
Madrid, Spain
START Madrid. Centro Integral Oncologico Clara Campal
Madrid, Spain
Clinica Universitaria de Navarra
Pamplona, Spain
Hospital Clinico Universitario de Valencia
Valencia, Spain
Sarah Cannon Research Institute
London, United Kingdom
The Christie
Manchester, United Kingdom
Royal Marsden Hospital (Sutton)
Sutton, United Kingdom
Trial contact
Vividion Clinical Trial Call Center
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/24/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.